Innocoll AG (INNL) Misses Q2 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Wall St futures drop as oil spikes after Trump rejects Iran peace proposal
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
- Oil gains 3% as US-Iran peace talks in stalemate
- Oppenheimer sees AI software winners as focus shifts to ROI
- Trump says men arrested at UK air base used by US were looking to do 'big damage'
- Nvidia releases AI safety software it says could have stopped Hugging Face hack
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Exclusive-Activist Jana pushes Fiserv to accelerate cost cuts and tap Palantir
Innocoll AG Announces Second Quarter 2015 Financial and Operating Results and Updates Late-Stage Product Portfolio Progress
August 14, 2015 8:00 AM EDTATHLONE, Ireland, Aug. 14, 2015 (GLOBE NEWSWIRE) -- Innocoll AG (Nasdaq: INNL), a global, commercial-stage, specialty pharmaceutical company that develops, manufactures and supplies a range of pharmaceutical products and medical devices using its proprietary collagen-based technologies, today announced financial and operating results for the three and six months ended June 30, 2015.
"We continued to execute on our objectives during the second quarter," said Tony Zook, Chief Executive Officer of Innocoll. "Both Cogenzia Phase 3 trials are now dosing patients and we expect to complete enrollment before the end of the first quarter of 2016. We were awarded... More
